1.American Diabetes Association. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2001;24(Suppl 1):S5-20.
2.
2.Pfeifer MA, Halter JB, Porte D Jr. Insulin secretion in diabetes mellitus. Am J Med. 1981;70:579-588.
3.
3.Bando Y, Toya D, Ushiogi Y, et al. The relationship of fasting plasma glucose values and other variables to 2-h postload plasma glucose in Japanese subjects. Diabetes Care. 2001;24:1156-1160.
4.
4.Grundy SM, Becker D, Clark LT, et al. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel l1l). JAMA. 2001;285:2486-2497.
5.
5.Reaven GM, Thompson LW, Nahum D, et al. Relationship between hyperglycemia and cognitive function in older NIDDM patients. Diabetes Care. 1990;13:16-21.
6.
6.Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
7.
7.Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med. 1995;122:561-568.
8.
8.Diabetes Control and Complications Trial Research Group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology. 1995;102:647-661.
9.
9.Diabetes Control and Complications Trial (DCCT) Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int. 1995;47:1703-1720.
10.
10.Turner RC, Holman RR, Cull CA, et al. (UK Prospective Diabetes Study [UKPDSJ Group). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
11.
11.Turner RC, Holman RR, Stratton IM, et al. (UK Prospective Diabetes Study [UKPDSJ Group). Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-865.
12.
12.Stratton IM, Adler Al, Neil AW, et al. (UK Prospective Diabetes Study [UKPDSJ Group). Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ. 2000;321:405-412.
13.
13.Pyorala K, Olsson AG, Pedersen TR, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997;20:614-620.
14.
14.Belanger C, Buring JE, Cook N, et al. Final report on the aspirin component of the ongoing Physicians' Health Study. N EngI J Med. 1989;321:129-135.
15.
15.Cook NR, Hebert PR, Manson DE, et al. Self-selected posttrial aspirin use and subsequent cardiovascular disease and mortality in the Physicians' Health Study. Arch Intern Med. 2000;160:921-928.
16.
16.Collins R, Peto R, Baigent P.et al. (Antiplatelet Trialists' Collaboration). Collaborative overview of randomised trials antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81-106.
17.
17.Knatterud GL, Fisher MR, Prior MJ, et al. Aspirin effects on mortality and morbidity in patients with diabetes mellitus: Early Treatment Diabetic Retinopathy Study (ETDRS) Report 14. JAMA. 1992;268:1292-1300.
18.
18.American Diabetes Association. Nutrition recommendations and principles for people with diabetes mellitus. Diabetes Care. 2001;24(Suppl 1):S44-S47.
19.
19.Franssila-Kallunki A, Rissanen A, Ekstrand A, et al. Effects of weight loss on substrate oxidation, energy expenditure, and insulin sensitivity in obese individuals. Am J Clin Nutr. 1992;55:356-361.
20.
20.Pratley RE, Hagberg JM, Dengel DR, et al. Aerobic exercise traininginduced reductions in abdominal fat and glucose-stimulated insulin responses in middle-aged and older men. J Am Geriatr Soc. 2000;48:1055-1031.
21.
21.Beebe C, O'Donnell M.Educating patients with type 2 diabetes. Nurs Clin North Am. 2001;36:375-386.
22.
22.www.armchairfitness.com (accessed November 16, 2001).
23.
23.Culy CR, Jarvis B.Repaglinide: review of its therapeutic use in type 2 diabetes mellitus. Drugs. 2001;61:1625-1660.
24.
24.Hanefield M, Dickinson S, Bouter KP, et al. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care. 2000;23:202-207.
25.
25.Keilson L, Mather S, Walter YH, et al. Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2000;86:1081-1088.
26.
26.Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281:2005-2012.
